ES3032462T3 - Method for the treatment of wwox associated diseases - Google Patents

Method for the treatment of wwox associated diseases

Info

Publication number
ES3032462T3
ES3032462T3 ES21777373T ES21777373T ES3032462T3 ES 3032462 T3 ES3032462 T3 ES 3032462T3 ES 21777373 T ES21777373 T ES 21777373T ES 21777373 T ES21777373 T ES 21777373T ES 3032462 T3 ES3032462 T3 ES 3032462T3
Authority
ES
Spain
Prior art keywords
wwox
gene
promoter
expression
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21777373T
Other languages
English (en)
Spanish (es)
Inventor
Rami Aqeilan
Srinivas Repudi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Application granted granted Critical
Publication of ES3032462T3 publication Critical patent/ES3032462T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES21777373T 2020-08-11 2021-08-11 Method for the treatment of wwox associated diseases Active ES3032462T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063064181P 2020-08-11 2020-08-11
US202163167277P 2021-03-29 2021-03-29
PCT/IL2021/050982 WO2022034591A1 (en) 2020-08-11 2021-08-11 Method for the treatment of wwox associated diseases

Publications (1)

Publication Number Publication Date
ES3032462T3 true ES3032462T3 (en) 2025-07-18

Family

ID=77910831

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21777373T Active ES3032462T3 (en) 2020-08-11 2021-08-11 Method for the treatment of wwox associated diseases

Country Status (9)

Country Link
US (1) US20230293726A1 (cg-RX-API-DMAC7.html)
EP (2) EP4196595B1 (cg-RX-API-DMAC7.html)
JP (1) JP7850136B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230051223A (cg-RX-API-DMAC7.html)
AU (1) AU2021324538A1 (cg-RX-API-DMAC7.html)
CA (1) CA3188895A1 (cg-RX-API-DMAC7.html)
ES (1) ES3032462T3 (cg-RX-API-DMAC7.html)
IL (1) IL300374A (cg-RX-API-DMAC7.html)
WO (1) WO2022034591A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116463413B (zh) * 2023-06-12 2023-10-03 佛山科学技术学院 猪间性病相关的wwox基因分子标记及其应用
US20260069548A1 (en) * 2024-06-18 2026-03-12 Synaptec Network, Inc. Systems and Methods of Exosome Mediated Delivery of Antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060811B2 (en) * 2000-10-13 2006-06-13 Board Of Regents, The University Of Texas System WWOX: a tumor suppressor gene mutated in multiple cancers
CA2624531A1 (en) * 2005-10-05 2007-04-19 Carlo M. Croce Wwox gene, vectors containing the same, and uses in treatment of cancer
MX2010011880A (es) * 2008-04-29 2011-05-25 Pharnext Nuevos enfoques terapeuticos para tratar la enfermedad del alzheimer y trastornos relacionados mediante una modulacion de la respuesta de estres celular.
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
CN105408483A (zh) 2013-03-15 2016-03-16 通用医疗公司 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向
WO2017147720A1 (en) * 2016-03-04 2017-09-08 Exerkine Corporation Method for treating a central nervous system disorder
MX2021000180A (es) * 2018-06-26 2021-06-08 Ribonova Inc Métodos para tratar la disfunción mitocondrial.
CA3160619A1 (en) * 2019-11-08 2021-05-14 Coave Therapeutics Modified adeno-associated virus vectors and delivery thereof into the central nervous system

Also Published As

Publication number Publication date
EP4196595B1 (en) 2025-03-12
KR20230051223A (ko) 2023-04-17
US20230293726A1 (en) 2023-09-21
EP4582143A3 (en) 2025-10-22
JP7850136B2 (ja) 2026-04-22
EP4196595A1 (en) 2023-06-21
IL300374A (en) 2023-04-01
JP2023537093A (ja) 2023-08-30
WO2022034591A1 (en) 2022-02-17
CA3188895A1 (en) 2022-02-17
AU2021324538A1 (en) 2023-03-09
EP4582143A2 (en) 2025-07-09

Similar Documents

Publication Publication Date Title
Steinberg et al. Modeling genetic epileptic encephalopathies using brain organoids
Xiao et al. Rescue of autosomal dominant hearing loss by in vivo delivery of mini dCas13X-derived RNA base editor
Qin et al. Vision rescue via unconstrained in vivo prime editing in degenerating neural retinas
Mei et al. Stage-specific deletion of Olig2 conveys opposing functions on differentiation and maturation of oligodendrocytes
Sakthivelu et al. Functional synapses between neurons and small cell lung cancer
Repudi et al. Neuronal deletion of Wwox, associated with WOREE syndrome, causes epilepsy and myelin defects
Liu et al. Ascl1 converts dorsal midbrain astrocytes into functional neurons in vivo
SG11202107813RA (en) Interneuron-specific therapeutics for normalizing neuronal cell excitability and treating dravet syndrome
US20210228741A1 (en) Methods and compositions to stimulate retinal regeneration
Huang et al. Tyrosine-mutated AAV2-mediated shRNA silencing of PTEN promotes axon regeneration of adult optic nerve
JP7850136B2 (ja) Wwox関連疾患の治療方法
Steinberg et al. WWOX-related neurodevelopmental disorders: models and future perspectives
Pulcrano et al. miR-218 promotes dopaminergic differentiation and controls neuron excitability and neurotransmitter release through the regulation of a synaptic-related genes network
JP2026041707A (ja) Slc26a4関連難聴を治療するための組成物及び方法
WO2022016055A1 (en) Methods and compositions for treatment of fragile x syndrome
CN116457025A (zh) 用于治疗wwox相关疾病的方法
Fu et al. Comparative transcriptomic profiling reveals a role for Olig1 in promoting axon regeneration
Williams et al. The assessment of adeno‐associated vectors as potential intrinsic treatments for brainstem axon regeneration
Obeid et al. Neuron-specific WWOX gene therapy produces dose-dependent, durable rescue in a model of WWOX-related epileptic encephalopathy
Lu Reversal of Aging via in Vivo Epigenetic Reprogramming
Gonzalez Ramos Enhancing neuronal inhibition by cell and gene therapy as a novel treatment for Epilepsy
Baughn Therapeutic Restoration of Stathmin-2 RNA Processing in TDP-43 Proteinopathies
Wang Neuronal Conversion of Human Glioblastoma Cells by Single Neuronal Transcription Factor
Alarcon-Martineza et al. Characterization of RNA editing and gene therapy with a compact CRISPR-Cas13 in the retina
Abati In vivo and in vitro evaluation of the combination of RNA interfering and gene therapy for treating Mitofusin2-related diseases